Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients: An Open Labelled, Randomized, Multicentered, Controlled Trial

NCT01351636 is registered in ClinicalTrials.gov with Marubeni Pharmaceuticals (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT01351636
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01351636 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients: An Open Labelled, Randomized, Multicentered, Controlled Trial
Lead sponsor
Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2011
Completion date
October 10, 2018
Enrollment
300 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease